348 results on '"Eşkazan, Ahmet Emre"'
Search Results
2. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
3. Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial
4. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
5. Elevación de SPINK2 en leucemia mieloide aguda
6. Upregulation of SPINK2 in acute myeloid leukemia
7. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
8. Kikuchi Fujimoto disease as the presenting component of VEXAS syndrome: a case report of a probable association
9. Clinical Application of Biomarkers for Hematologic Malignancies
10. Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions
11. Chronic Myeloid Leukemia in Renal Transplantation Patients in the Era of Tyrosine Kinase Inhibitors: A Case Report and Review of the Literature.
12. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
13. Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
14. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
15. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score
16. Novel therapeutic approaches in chronic myeloid leukemia
17. Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP)
18. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options
19. Fatal panresistant Lomentospora prolificans fungemia in a patient with aplastic anemia: First report from Türkiye
20. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations
21. Flow Cytometric Analysis of Lymphocyte Subsets of Covid-19 Patients from A Single Centre in Turkey
22. Asciminib in chronic myeloid leukemia: many questions still remain to be answered
23. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
24. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
25. Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
26. Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
27. A cross-sectional study on restless legs syndrome (RLS) in polycythemia vera (PV): is iron deficiency the only culprit?
28. Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis
29. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
30. Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
31. Editorial: Advances in the treatment of chronic myeloid leukemia
32. ATRA+ATO combination in APL – A commentary on “evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades” by Teng-Fei et al.
33. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review
34. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options
35. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults.
36. Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
37. Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
38. Plasma exchange therapy in ANCA-associated vasculitis: A single-center retrospective cohort study
39. Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
40. Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic
41. Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?
42. Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System
43. Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
44. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
45. Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts
46. Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?
47. Rare and Aggressive Disease: Challenge
48. A Rare and Aggressive Disease: Answer
49. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion
50. Plasma exchange therapy in systemic lupus erythematosus: A single-center retrospective cohort study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.